When: May 4, 2014
Where: Seaport World Trade Center, Boston, MA
Proteins and peptides represent a significant segment of the therapeutics spectrum with many promising candidates under early development or in late-stage clinical trials. Several of these molecules are poised to make a substantial impact, especially in the under-represented or unrepresented categories such as neurological disorders and neurodegenerative diseases. A key challenge to be overcome with protein and peptide based biologics, however, is their effective delivery to the target site while achieving the optimum balance of stability, safety, bioavailability, and patient compliance. This short course will provide a broad overview of the opportunities and challenges in the development of the next generation of protein and peptide therapeutic delivery systems.
weems-Texas Medicaid Health Home Pilot Project Evaluation MethodsNASHP HealthPolicy
Leslie A. Weems, LMSW, Senior Policy Analyst and Project Manager, Medicaid/CHIP Division, Texas Health and Human Services Commission discusses Texas Medicaid Health Home Pilot Project Evaluation Methods at the New Tactics for Building Medical Homes in State Medicaid and CHIP Programs webinar
With significant unmet needs for RA patients, it's more important than ever to overcome your Rheumatoid Arthritis development pain points with an experienced and trusted partner.
A member of the Ockham Oncology Scientific Advisory Board, Dr. Schnipper presented to Ockham employees “Cancer is Still a Major Problem.” This presentation discusses possible developments in clinical trials and new ways of thinking about cancer. Take a look!
weems-Texas Medicaid Health Home Pilot Project Evaluation MethodsNASHP HealthPolicy
Leslie A. Weems, LMSW, Senior Policy Analyst and Project Manager, Medicaid/CHIP Division, Texas Health and Human Services Commission discusses Texas Medicaid Health Home Pilot Project Evaluation Methods at the New Tactics for Building Medical Homes in State Medicaid and CHIP Programs webinar
With significant unmet needs for RA patients, it's more important than ever to overcome your Rheumatoid Arthritis development pain points with an experienced and trusted partner.
A member of the Ockham Oncology Scientific Advisory Board, Dr. Schnipper presented to Ockham employees “Cancer is Still a Major Problem.” This presentation discusses possible developments in clinical trials and new ways of thinking about cancer. Take a look!
The Use Of Error and Uncertainty Methods in the Medical LaboratoryShrineCaete
Error and uncertainty methods are complementary when evaluating measurement data. Error methods compared with uncertainty methods offer simpler, more intuitive and practical procedures for calculating measurement uncertainty and conducting quality assurance in laboratory medicine.
Speaker Presentation from U.S. News Healthcare of Tomorrow leadership summit, Nov. 1-3, 2017 in Washington, DC. Find out more about this forum at www.usnewshot.com.
GlobalSurg global surgery research collaboration - GASOC presentation in OxfordDr Edward Fitzgerald
GlobalSurg was established to represent practising surgeons from around the world and support collaborative international research into surgical outcomes by fostering local, national and international research networks.
Our growing network now includes over 5000 clinicians in more than 100 countries. The ethos is inclusive and collaborative: our international cohort studies are open to all collaborators, including medical students, clinical officers, doctors, nurses and researchers.
We run annual research prioritisation events, allowing surgeons from all over world to contribute to the direction of the group.
Our cohort studies aim to give grass-root surgeons the opportunity to participate in major projects. They are designed to ensure easy delivery by local surgeons and will not require extra resources or funding. Every researcher who contributes data into a cohort study is a Pubmed-citable collaborator on study papers which will be published under one main name – GlobalSurg – to represent our group effort.
In our final webinar of the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the advantages of good formulation.
Claire Patterson, Seda Pharmaceutical Development Services
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at Complex Medicine and articulates what the commercial opportunity could be.
David Cook, Blueberry Therapeutics
A brief presentation on medicines optimisation and the input a clinical pharmacist can make in improving treatment outcomes for patients and help make evidence led cost effective improvements for the wider NHS.
ECO 11: Medicines Optimisation Through Precision - Sir Munir PirmohamedInnovation Agency
Munir Pirmohamed discusses the potential impact of medicines optimisation in terms of ensuring the right patients get the right choice if medicine at the right time. He presents a case history of over prescription and introduces three examples of medicines optimisation through use of genetics, big data, and pharmacogenetics profiling.
Value of Medical Laboratory Science Personnel and Clinical Laboratory Service...Sheleste Vergara
Web-Based Presentation by:
Sheleste Anne Marie R. Vergara
BMLS - 1B
American Society for Clinical Laboratory Science, House of Delegates. ASCLS Position Paper: Patient Safety and Clinical Laboratory Science [Internet]. 2015 Jul [cited 14 Dec 2020]
https://ascls.org/value-of-clinical-laboratory-services/
Webinar: Increase research efficiency and enable collaboration with the IDBS ...IDBS
Streamline patient stratification together with omics and sample management
Find out how the solution enables research scientists and clinicians across Healthcare, Pharma and other Life Sciences organizations to create a comprehensive research platform that empowers high quality decision-making. It provides the building blocks to allow clinical researchers to capture and curate their data, to manage ontologies, and to integrate, search and visualize data from clinical, biobanks and omics data sources.
In this webinar you will see how to:
- improve sample management
- capture Data Provenance
- stratify patient populations
- explore omics data in the context of clinical phenotype
- facilitate a results sharing culture between departments and collaborators
To view the webinar: http://www.idbs.com/en/news-events/list-of-webinars/2014/03/increase-research-efficiency-and-enable-collaboration-with-the-idbs-translational-science-solution/
Webinar Series on Demystifying Phases in Clinical Trials & COVID-19 Updates organized by Institute for Clinical Research (ICR), NIH
Speaker: Dr. Salina Abdul Aziz. MREC Chairperson
More information, please visit: https://clinupcovid.mailerpage.com/resources/p9f2i7-introduction-to-phase-2-3-trial-s
Optimizing Protocol Design and Enhancing Patient Enrollment Case Study Covance
An emerging biopharmaceutical company was considering development of a pharmacologic agent for treatment of patients with diabetic kidney disease (DKD).
Principles of evidence based medicine.
EBM means integrating individual clinical expertise with the best available external evidence from systematic research.
The Use Of Error and Uncertainty Methods in the Medical LaboratoryShrineCaete
Error and uncertainty methods are complementary when evaluating measurement data. Error methods compared with uncertainty methods offer simpler, more intuitive and practical procedures for calculating measurement uncertainty and conducting quality assurance in laboratory medicine.
Speaker Presentation from U.S. News Healthcare of Tomorrow leadership summit, Nov. 1-3, 2017 in Washington, DC. Find out more about this forum at www.usnewshot.com.
GlobalSurg global surgery research collaboration - GASOC presentation in OxfordDr Edward Fitzgerald
GlobalSurg was established to represent practising surgeons from around the world and support collaborative international research into surgical outcomes by fostering local, national and international research networks.
Our growing network now includes over 5000 clinicians in more than 100 countries. The ethos is inclusive and collaborative: our international cohort studies are open to all collaborators, including medical students, clinical officers, doctors, nurses and researchers.
We run annual research prioritisation events, allowing surgeons from all over world to contribute to the direction of the group.
Our cohort studies aim to give grass-root surgeons the opportunity to participate in major projects. They are designed to ensure easy delivery by local surgeons and will not require extra resources or funding. Every researcher who contributes data into a cohort study is a Pubmed-citable collaborator on study papers which will be published under one main name – GlobalSurg – to represent our group effort.
In our final webinar of the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at the advantages of good formulation.
Claire Patterson, Seda Pharmaceutical Development Services
Our first webinar in the MDC Connects Series 2021 | A Guide to Complex Medicines.
This slide deck takes a closer look at Complex Medicine and articulates what the commercial opportunity could be.
David Cook, Blueberry Therapeutics
A brief presentation on medicines optimisation and the input a clinical pharmacist can make in improving treatment outcomes for patients and help make evidence led cost effective improvements for the wider NHS.
ECO 11: Medicines Optimisation Through Precision - Sir Munir PirmohamedInnovation Agency
Munir Pirmohamed discusses the potential impact of medicines optimisation in terms of ensuring the right patients get the right choice if medicine at the right time. He presents a case history of over prescription and introduces three examples of medicines optimisation through use of genetics, big data, and pharmacogenetics profiling.
Value of Medical Laboratory Science Personnel and Clinical Laboratory Service...Sheleste Vergara
Web-Based Presentation by:
Sheleste Anne Marie R. Vergara
BMLS - 1B
American Society for Clinical Laboratory Science, House of Delegates. ASCLS Position Paper: Patient Safety and Clinical Laboratory Science [Internet]. 2015 Jul [cited 14 Dec 2020]
https://ascls.org/value-of-clinical-laboratory-services/
Webinar: Increase research efficiency and enable collaboration with the IDBS ...IDBS
Streamline patient stratification together with omics and sample management
Find out how the solution enables research scientists and clinicians across Healthcare, Pharma and other Life Sciences organizations to create a comprehensive research platform that empowers high quality decision-making. It provides the building blocks to allow clinical researchers to capture and curate their data, to manage ontologies, and to integrate, search and visualize data from clinical, biobanks and omics data sources.
In this webinar you will see how to:
- improve sample management
- capture Data Provenance
- stratify patient populations
- explore omics data in the context of clinical phenotype
- facilitate a results sharing culture between departments and collaborators
To view the webinar: http://www.idbs.com/en/news-events/list-of-webinars/2014/03/increase-research-efficiency-and-enable-collaboration-with-the-idbs-translational-science-solution/
Webinar Series on Demystifying Phases in Clinical Trials & COVID-19 Updates organized by Institute for Clinical Research (ICR), NIH
Speaker: Dr. Salina Abdul Aziz. MREC Chairperson
More information, please visit: https://clinupcovid.mailerpage.com/resources/p9f2i7-introduction-to-phase-2-3-trial-s
Optimizing Protocol Design and Enhancing Patient Enrollment Case Study Covance
An emerging biopharmaceutical company was considering development of a pharmacologic agent for treatment of patients with diabetic kidney disease (DKD).
Principles of evidence based medicine.
EBM means integrating individual clinical expertise with the best available external evidence from systematic research.
CHI’s Inaugural Biologics Formulation and Delivery Summit will provide a forum for focused discussions on current challenges and opportunities in delivery of biotherapeutics. This 2-part summit will discuss various formulation and device-based approaches for designing physiologically relevant, patient friendly, targeted biologics products.
Part 1: Formulation Strategies for Improved Delivery of Biologics (May 5-6)
Part 2: New Technologies for Biologics Delivery and Targeting (May 6-7)
The dream of any physician and consequently every patient is to receive the right treatment in the right time with cost effectiveness. To achieve this goal, the 3 pillars: evidence based medicine, clinical research innovation & resources utilization should be integrated efficiently.
In this presentation, I'll try to comprehensively review the following:
1- How are we used to perform clinical trials in Oncology?
2- Does it fits in today’s needs?
3- Integration of biology knowledge in shaping drug development
4- New Clinical trial designs “Can they offer solution for accelerating drug development?”
5- The supporting infrastructure role in clinical trial execution
“The Evolution of Pharmaceutical Biotechnology – Science, Strategies, Products, and Regulations”
Shows the latest developments in pharmaceutical biotechnology and provides a broad overview of biotherapeutic & biosimilar regulations globally and in the EU
Immunogenicity and Bioassay Summit, Baltimore, MD November 17-19, 2015David Cunningham
Thinking about attending the Immunogenicity and Bioassay Summit, but have questions? I would be more than happy to walk you through the program agenda, pricing options and answer any questions you may have. In the meantime, don’t forget about the savings deadline coming up Friday, October 16th!
Call David at 781-972-5472 if you would like to join us!
We have 13 research and development projects within:
• Research
• Oncology
• Respiratory, Inflammation and Autoimmunity
• Cardiovascular and Metabolic Disease
• Antibody Discovery and Protein Engineering
• Pathology
• Biopharmaceutical Development
• Cell Culture and Fermentation Sciences
• Formulation Sciences
• Analytical Biotechnology Science
This 3-day event is the meeting place for international and domestic scientists to share case studies and project updates, showcase new techniques and form collaborations that pave the way towards the future of China’s biopharmaceutical industry.
PepTalk: The Protein Science Week is an annual gathering where industry experts from around the world convene to share case studies, unpublished data, breakthroughs and solutions that support and enhance research, and to gain new perspectives on the evolution of biologics.
Next-Gen Clinical Pharmacy AI and Internet-Based Decision SupportShymaaShehata1
Welcome to our Presentation on Next-Gen Clinical Pharmacy AI and Internet-Based Decision Support. In this presentation, we explore the advancements in artificial intelligence and how it is revolutionizing the field of clinical pharmacy.
Headlines
using different Clinical Decision Support Tools including:
1_ FREE Mobile Applications for android and iPhone
2_ FREE Website
3_FREE scoring system in medical & surgical ICU
4_FREE Ai tools used in medicine
5_Using Chatgpt & Gemini in medicine
6_Tips & Tricks in management of clinical case scenarios
also, we will explain the following in details:
1-we discuss the potential of AI in providing decision support to healthcare professionals, enhancing patient care, and improving medication management.
2-we shed light on the cutting-edge advancements in clinical pharmacy. Through the power of artificial intelligence, healthcare professionals can now access intelligent decision support systems that aid in making informed choices regarding patient care and medication management.
3-we dive into the transformative role of artificial intelligence in the field of pharmacy. Learn how AI-powered decision support systems are revolutionizing patient care, medication management, and healthcare outcomes.
Stay tuned to
1- learn about the latest developments and future prospects in this exciting area of pharmacy,
2- explore the potential benefits and challenges of integrating AI into clinical pharmacy practice.
3- explore the possibilities and implications of this next-generation technology in clinical pharmacy practice.
PEGS Europe Protein & Antibody Engineering Summit 2014 AgendaNicole Proulx
PEGS Europe is the largest European event covering all aspects of protein and antibody engineering. With two consecutive years of 40% growth in attendance, and another year of expanded program coverage, this year’s event will feature:
•500 attendees
•150 technical presentations
•70+ scientific posters
•40+ sponsors & exhibitors
•Dedicated networking opportunities
•Exclusive exhibit & poster hours
•Interactive roundtable, breakout & panel discussions
Drug Delivery & Formulation Summit 2019Diogo Ribeiro
On 19 & 20 September 2019, Munich (Germany) will host the BioTech Pharma Summit: Drug Delivery & Formulation 2019 conference. This year’s event will bring together leaders and senior industry experts in formulation, delivery and product development. Presentations will assess recent technological innovations and discuss their impact on product improvement and patient experience.
CHI's Next Generation Dx Summit 2022 | August 22-24, 2022 | Washington, D.C.James Prudhomme
Advancing Diagnostics Together
We are proud to host Cambridge Healthtech Institute's Fourteenth Annual Next Generation Dx Summit which will take place in-person at the Grand Hyatt Washington, D.C. on August 22-24. The Next Generation Dx Summit is the nexus for key opinion leaders across the world to share recent progress in diagnostic advancement and technology innovation. The event provides a valuable window on how point-of-care, infectious disease, liquid biopsy and companion diagnostics are changing the standard of care. Now in its fourteenth year, the Next Generation Dx Summit is a must-attend event with complete coverage of the most timely and important topics for the industry.
CHI's Targeting Stromal Cells in Cancer and Inflammatory Diseases Conference ...James Prudhomme
This virtual meeting will highlight cutting-edge science and provide insight into recent developments towards therapeutic stromal cell targeting in cancer and chronic inflammatory diseases. View full details and register: https://www.healthtech.com/stroma-conference
CHI's Next Generation Dx Summit | August 25-27, 2020 | Washington, DCJames Prudhomme
Next Generation Dx Summit brings together more than 800 international diagnostic professionals working in the field and offers unparalleled insight from the comprehensive programming and networking with key opinion leaders in the industry. The event is unique in the marketplace. This year the coverage spans cell- and cell-free biopsies, commercialization, reimbursement, biomarkers and companion diagnostics for immunotherapy, point-of-care testing, infectious disease, microfluidics and precision medicine. Now in its twelfth year, Next Generation Dx Summit is a must-attend event with complete coverage of the most timely and important issues for the industry.
CHI's 10th Annual Next Generation Dx Summit, August 20-24, 2018, Washington, DCJames Prudhomme
Next Generation Dx Summit has grown to more than 1,000 international diagnostic professionals working in the field and offers unparalleled insight from the comprehensive programming and networking with key opinion leaders in the industry. The event is unique in the marketplace. This year the coverage spans cell- and cell-free biopsies, commercialization, reimbursement, biomarkers and companion diagnostics for immunotherapy, point-of-care testing, infectious disease, microfluidics and precision medicine. Now in its tenth year, Next Generation Dx Summit is a must-attend event with complete coverage of the most timely and important issues for the industry.
CHI's Bioassays for Immuno-Oncology Symposium, Oct. 23, 2017 in Washington, DCJames Prudhomme
Biological assays demonstrating drug characteristics such as potency, mechanism-of-action, and stability, are one of the most critical components of an FDA biologic submission. However, with more complex mechanisms-of-action, immunotherapies add a layer of difficulty to bioassay selection and development. At Cambridge Healthtech Institute's Inaugural Bioassays for Immuno-Oncology symposium, experts in bioassays for immuno-oncology therapies will discuss selection, development, and standards for bioassays and immunoassays. Special attention will be given to understanding the mechanism-of-action for immunotherapies, whether they be antibody- or cell-based. Overall, this one-day immersive symposium will outline a product life cycle approach for developing and implementing biological assays from preclinical studies to clinical development. This symposium is part of the Immunogenicity & Bioassay Summit.
Immuno-Oncology Course, organized by Healthcare Education ServicesJames Prudhomme
The Immuno-Oncology one-day course provides an overview of the rapidly evolving subject of immune-oncology. Delegates are offered a thorough understanding of the basics of tumor immunology as well as the essentials of immunotherapy and its application in cancer medicine. Examples of both how biologics work in the practice of oncology and of the challenges presented are demonstrated.
The program has been developed specifically to support the needs of the pharmaceutical, biotechnology and medical technology industry personnel. It is ideal for individuals with little understanding of the immunotherapy of cancer and those with an existing basic knowledge. Detailed presentations and discussion with Healthcare’s experienced and knowledgeable faculty enable thorough insight to this important subject area.
Introduction to Cancer: Focus on Solid Tumors Course, organized by Healthcare...James Prudhomme
Delegates attending this course will benefit from an introductory overview of the terminology and classification of cancer and the principle issues in its treatment. Commonly available anti-cancer drugs will be reviewed, including immunotherapies. The range of side-effects of cancer treatments will be studied in detail. Quality-of-life issues in terms of overall assessment and result interpretation will also be discussed.
Detailed consideration will be given to the treatment of major tumor types: breast, lung, upper gastrointestinal (GI), colorectal, melanoma, ovarian and prostate cancer.
Hematologic Cancers - An Introduction Course, organized by Healthcare Educati...James Prudhomme
This course reviews the hematological system and provides an overview on the spectrum of hematologic cancers. The expert teaching team, comprising currently practising physicians, guides course attendees through the pathophysiology of Hematologic Cancers - An Introduction such as leukemias, lymphomas and myeloma. Common treatments and management of these malignancies are discussed as well as the challenges these treatments present to patients. The issues and complications of bone marrow and stem cell transplant are also reviewed. Case studies and open discussion form an integral part of the program.
Overcome Operational Challenges in Biomarker-driven Clinical TrialsJames Prudhomme
Cambridge Healthtech Institute offers two back-to-back symposia on the operational aspects of precision medicine trials and the improvement of infrastructure to better support those trials. The 2nd Annual Managing Precision Medicine Trials Symposium (January 24-25, 2017) focuses on strategizing design for biomarker driven trials and novel clinical trial design. The Inaugural Sample, Lab and Diagnostics Services in Clinical Trials Symposium (January 25-26, 2017) focuses on clinical sample management and sourcing and diagnostics services.
Cambridge Healthtech Institute (CHI) is pleased to announce the Third Annual FAST: Functional Analysis and Screening Technologies Congress. Now in its third year, the FAST Congress brings you the latest technologies and research in cellular screening.
The Third Annual Phenotypic Drug Discovery meeting will return with new updates and case studies in phenotypic screening, high-content analysis, physiologically-relevant cellular models, chemical genomics and chemical proteomics. The rapidly evolving area of 3D cellular models will be addressed by two back-to-back meetings, with the Inaugural 3D Cell Culture: Organoid, Spheroid, and Organ-on-a-Chip Models meeting focusing on the new predictive cellular models for drug discovery and toxicity assessment. It will review the use of primary and stem cells, complex co-culture cell models, tumor spheroid models, novel organ-on-a-chip models for efficacy and safety screening, functional analysis, and compound profiling. The Third Annual Screening and Functional Analysis of 3D Models meeting will follow with case studies of phenotypic and high-content screening of complex 3D cellular systems for compound and target selection.
The 2014 Congress attracted more than 250 senior delegates, representing over 160 companies from 20 countries. With half of the attendees from big pharma and biotech and a third from academia and government, the FAST Congress offers exclusive networking opportunities with diverse international attendance. Please join our focused Screening event and learn from 60+ scientific presentations, an assortment of educational courses, 20+ exhibitors and your fellow expert delegates. We look forward to seeing you at the event.
Next Generation Dx Summit 2015 - Moving Assays to the ClinicJames Prudhomme
The Next Generation Dx Summit, entering its seventh year, brings together more than 800 diagnostics professionals from across the world, providing comprehensive programming and valuable networking opportunities. Spanning from clinical diagnostics to business strategy, this year’s expanded program encompasses predictive cancer biomarkers, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, cell-free DNA, commercialization, cancer immunotherapy, and reimbursement. With widespread coverage of all the most relevant diagnostics topics, the Next Generation Dx Summit promises to be a must-attend event to hear the latest announcements and developments in this rapidly evolving field.
Cambridge Healthtech Institute's fourth annual Clinical Trial Oversight Summit will feature four co-located conferences covering best practices and recent trends relevant to clinical research monitoring, auditing, clinical quality assurance, site management, and vendor oversight. This four-day summit will include presentations from experts, case studies, interactive breakout discussion groups, workshops, and networking opportunities. Themes throughout will include risk-based approaches to clinical trial management, implementing quality systems-based approaches to GCP compliance, ensuring reliable study data, responding to the evolving regulatory landscape, and preparing sites and clinical research partners for inspection-readiness.
Call for Posters: Functional Analysis & Screening TechnologiesJames Prudhomme
Cambridge Healthtech Institute (CHI) is accepting scientific posters from industry & academic researchers on improving the screening success of rate drugs using 3D models & phenotypic screening for display at it's second annual "FAST: Functional Analysis & Screening Technologies Congress" to be held on November 17-19, 2014. www.FASTCongress.com
Join us in Boston this coming Fall to attend Cambridge Healthtech Institute's (CHI) 2nd Annual FAST: Functional Analysis & Screening Technologies Congress on November 17-19, 2014 and meet with a community of 250+ biologists, screening managers, assay developers, engineers and pharmacologists dedicated to improving in vitro cell models and phenotypic screening to advance drug discovery and development at 6 conferences: Phenotypic Drug Discovery (Part I & II), Engineering Functional 3D Models, Screening and Functional Analysis of 3D Models, Organotypic Culture Models for Toxicology and Physiologically-Relevant Cellular Tumor Models for Drug Discovery. Delegates have the opportunity to share insights in interactive panel discussions and connect during networking breaks. View innovative technologies and scientific research revolutionizing early-stage drug discovery in the exhibit/poster hall.
Short Courses at CHI's Immunogenicity and Bioassay Summit 2014James Prudhomme
Cambridge Healthtech Institute (CHI) will once again offer comprehensive training at the Sixth Annual Immunogenicity and Bioassay Summit 2014. The following courses are led by well-respected professionals in the pharmaceutical industry who have much experience in helping investigators overcome their difficulties with these challenging assays and with risk assessment. Delegates will enjoy an intimate setting with their peers and instructors and have the opportunity to ask questions and exchange experiences.
Make Plans to Attend the Number 1 Immunogenicity and Bioassay Event Bringing Together Industry,
Academia and Regulatory Authorities. Featuring 8 FDA Presenters!
Course: Development of High-Dose Biologics Dosage FormsJames Prudhomme
Course: Development of High Dose Biologics Dosage Forms will be held on May 6, 2014 in Boston, MA - part of the Biologics Formulation & Delivery Summit.
PK/PD and Immunogenicity Conferences, May 2014, Boston, MA - part of PEGSJames Prudhomme
The Safety Stream at PEGS will guide attendees through the process of developing a comprehensive immunogenicity and PK/PD strategy to ensure successful biologics. With a focus on novel constructs, high level science and expert advice will examine assay strategies, management of product immunogenicity, and modeling PK/PD to improve drug performance. Risk assessment and regulatory guidance to ensure clinical success and a competitive advantage will also be addressed.
Earliest Galaxies in the JADES Origins Field: Luminosity Function and Cosmic ...Sérgio Sacani
We characterize the earliest galaxy population in the JADES Origins Field (JOF), the deepest
imaging field observed with JWST. We make use of the ancillary Hubble optical images (5 filters
spanning 0.4−0.9µm) and novel JWST images with 14 filters spanning 0.8−5µm, including 7 mediumband filters, and reaching total exposure times of up to 46 hours per filter. We combine all our data
at > 2.3µm to construct an ultradeep image, reaching as deep as ≈ 31.4 AB mag in the stack and
30.3-31.0 AB mag (5σ, r = 0.1” circular aperture) in individual filters. We measure photometric
redshifts and use robust selection criteria to identify a sample of eight galaxy candidates at redshifts
z = 11.5 − 15. These objects show compact half-light radii of R1/2 ∼ 50 − 200pc, stellar masses of
M⋆ ∼ 107−108M⊙, and star-formation rates of SFR ∼ 0.1−1 M⊙ yr−1
. Our search finds no candidates
at 15 < z < 20, placing upper limits at these redshifts. We develop a forward modeling approach to
infer the properties of the evolving luminosity function without binning in redshift or luminosity that
marginalizes over the photometric redshift uncertainty of our candidate galaxies and incorporates the
impact of non-detections. We find a z = 12 luminosity function in good agreement with prior results,
and that the luminosity function normalization and UV luminosity density decline by a factor of ∼ 2.5
from z = 12 to z = 14. We discuss the possible implications of our results in the context of theoretical
models for evolution of the dark matter halo mass function.
Nutraceutical market, scope and growth: Herbal drug technologyLokesh Patil
As consumer awareness of health and wellness rises, the nutraceutical market—which includes goods like functional meals, drinks, and dietary supplements that provide health advantages beyond basic nutrition—is growing significantly. As healthcare expenses rise, the population ages, and people want natural and preventative health solutions more and more, this industry is increasing quickly. Further driving market expansion are product formulation innovations and the use of cutting-edge technology for customized nutrition. With its worldwide reach, the nutraceutical industry is expected to keep growing and provide significant chances for research and investment in a number of categories, including vitamins, minerals, probiotics, and herbal supplements.
Seminar of U.V. Spectroscopy by SAMIR PANDASAMIR PANDA
Spectroscopy is a branch of science dealing the study of interaction of electromagnetic radiation with matter.
Ultraviolet-visible spectroscopy refers to absorption spectroscopy or reflect spectroscopy in the UV-VIS spectral region.
Ultraviolet-visible spectroscopy is an analytical method that can measure the amount of light received by the analyte.
Multi-source connectivity as the driver of solar wind variability in the heli...Sérgio Sacani
The ambient solar wind that flls the heliosphere originates from multiple
sources in the solar corona and is highly structured. It is often described
as high-speed, relatively homogeneous, plasma streams from coronal
holes and slow-speed, highly variable, streams whose source regions are
under debate. A key goal of ESA/NASA’s Solar Orbiter mission is to identify
solar wind sources and understand what drives the complexity seen in the
heliosphere. By combining magnetic feld modelling and spectroscopic
techniques with high-resolution observations and measurements, we show
that the solar wind variability detected in situ by Solar Orbiter in March
2022 is driven by spatio-temporal changes in the magnetic connectivity to
multiple sources in the solar atmosphere. The magnetic feld footpoints
connected to the spacecraft moved from the boundaries of a coronal hole
to one active region (12961) and then across to another region (12957). This
is refected in the in situ measurements, which show the transition from fast
to highly Alfvénic then to slow solar wind that is disrupted by the arrival of
a coronal mass ejection. Our results describe solar wind variability at 0.5 au
but are applicable to near-Earth observatories.
This pdf is about the Schizophrenia.
For more details visit on YouTube; @SELF-EXPLANATORY;
https://www.youtube.com/channel/UCAiarMZDNhe1A3Rnpr_WkzA/videos
Thanks...!
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.Sérgio Sacani
The return of a sample of near-surface atmosphere from Mars would facilitate answers to several first-order science questions surrounding the formation and evolution of the planet. One of the important aspects of terrestrial planet formation in general is the role that primary atmospheres played in influencing the chemistry and structure of the planets and their antecedents. Studies of the martian atmosphere can be used to investigate the role of a primary atmosphere in its history. Atmosphere samples would also inform our understanding of the near-surface chemistry of the planet, and ultimately the prospects for life. High-precision isotopic analyses of constituent gases are needed to address these questions, requiring that the analyses are made on returned samples rather than in situ.
THE IMPORTANCE OF MARTIAN ATMOSPHERE SAMPLE RETURN.
Course: Challenges and Opportunities in Protein and Peptide Drug Delivery
1. Short Course: Organized by Cambridge Healthtech Institute
Challenges and Opportunities in Protein and Peptide Drug Delivery
Sunday, May 4, 2014 | 10:00 am - 2:00 pm
Seaport World Trade Center, Boston, MA
Proteins and peptides represent a significant segment of the therapeutics spectrum with many
promising candidates under early development or in late-stage clinical trials. Several of these
molecules are poised to make a substantial impact, especially in the under-represented or
unrepresented categories such as neurological disorders and neurodegenerative diseases. A key
challenge to be overcome with protein and peptide based biologics, however, is their effective delivery
to the target site while achieving the optimum balance of stability, safety, bioavailability, and patient
compliance. This short course will provide a broad overview of the opportunities and challenges in the
development of the next generation of protein and peptide therapeutic delivery systems.
Therapeutic spectrum
• Introduction to biologics based on proteins and peptides
• Different classes of protein and peptide biologics
• Representative examples in clinical use
• New molecules under development – next-generation biologics
• Clinical needs and opportunities
• Clinical advantages of biologics over small molecules
• Current niche served by protein and peptide biologics
• Unrepresented clinical indications and opportunities
• Key challenges in protein and peptide delivery
• Issues related to stability
• Route of administration
• Biological barriers (e.g. blood-brain barrier)
• Bioavailability for therapeutic benefit
• Safety/toxicity balance
New developments in enhancing protein stability
• Use of biostable/synthetic scaffolds
• Chemical modifications
• Packaging in nano and mesoporous carriers
• Molecular chaperones for enhanced serum stability
2. New developments in overcoming delivery challenges
• Integration of delivery vectors with biologics
• Protein/peptide API-based nanomaterials
• Alternate routes/interfaces for administration
• Transgenic delivery systems
Future directions in protein and peptide delivery
• New clinical indications
• Novel delivery systems
• New routes of administration
Instructor: Pankaj Karande, Ph.D., Assistant Professor, Department of Chemical & Biological
Engineering, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute
How to Register:
Web: http://chidb.com/register/2014/pfm/reg.asp
Call: 781-972-5400
Email: reg@healthtech.com
This course is part of the Biologics, Formulation & Delivery Summit.
www.healthtech.com/biologics-delivery
